07:00 , Sep 22, 2008 |  BC Week In Review  |  Company News

Neurotune, Brane Discovery deal

Neurotune acquired two programs in neuropathic pain from Brane for an undisclosed amount of cash and stock. The programs, which Neurotune said could focus on indications such as osteoarthritis pain and diabetic neuropathy, are in...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Clinical News

BND-11624: Phase I started

Brane began a double-blind, placebo-controlled, single-ascending dose, Swiss Phase I trial in 24 healthy volunteers. Brane Discovery s.r.l. , Gerenzano, Italy   Product: BND-11624   Business: Neurology   Molecular target: NA   Description: A pyrrolidinone...
07:00 , Apr 30, 2007 |  BC Week In Review  |  Company News

NiKem neurology news

NiKem spun out all its R&D assets into Brane Discovery s.r.l. (Milan, Italy). The newco has two products in preclinical development: BND-001, which targets a G protein-coupled receptor (GPCR), to treat Parkinson's disease (PD), and...